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the debate about surgical resection of primary tumor (pt) in de novo metastatic breast cancer (MBc) 
patients persists. We explored this approach’s outcomes in patients included in a retrospective registry, 
named El Álamo, of breast cancer patients diagnosed in Spain (1990–2001). In this analysis we only 
included de novo MBC patients, 1415 of whom met the study’s criteria. Descriptive, Kaplan-Meier and 
Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-
organ metastasis (skin/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was 
performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence 
of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median 
follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR = 0.59, p < 0.0001) 
in the S- and non-S groups, respectively. The S-group OS benefit remained statistically and clinically 
significant regardless of metastatic location, histological type, histological grade, hormone receptor 
status and tumor size. PT surgery (versus no surgery) was associated with an OS benefit suggesting that 
loco-regional PT control may be considered in selected MBC patients. Data from randomized controlled 
trials are of utmost importance to confirm these results.
In western countries metastatic breast cancer (MBC) at first diagnosis is characterized by incidence rates rang-
ing between 4% and 10%, low rates of long-term survival, and estimates of life expectancy between 18 and 24 
months1,2. Thus, the consensus management of patients presenting MBC has been palliative, focused on pro-
longing survival and improving quality of life2. Although the impact of new treatment strategies on response 
rates is clinically meaningful, benefits of new treatments on overall survival (OS) are harder to attain in the 
metastatic setting3–5. Nevertheless, survival gains for MBC patients have been reported6–8, suggesting that new 
therapeutic strategies could potentially improve the clinical practice and management of MBC patients. In 
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addition, breakthroughs in diagnostic technology (i.e., PET/TC) now allow the detection of early and asympto-
matic metastatic disease. The lower tumor burden in limited stage IV disease makes it potentially more responsive 
to treatment9–11.
Because of these advancements in diagnostics and therapies, clinicians are increasingly acknowledging that 
MBC patient survival prospects are improving12–14 and even challenging the paradigm of incurability in selected 
cases of de novo MBC patients15–17, particularly those with oligometastatic disease18–20. Stemming from the 
“long-term MBC survivor profile” concept, the role of local therapies is being re-examined beyond its traditional 
palliative intent and into a potentially curative one21.
Retrospective reports and meta-analyses suggest a survival benefit associated with surgery of the primary 
tumor (PT) in MBC patients, especially when surgical margin is tumor free22–24. Thus, surgery may be considered 
an option in the algorithm for management of selected MBC patients besides the generally accepted hygienic 
indication as prevention of local complications (infection, ulceration or bleeding). The achievement of locore-
gional control of the tumor has been tried through surgery but radiotherapy’s role has also been studied in this 
setting25,26. Due to the retrospective nature of these studies, reasonable concerns emerged regarding the consist-
ency of the available clinical data27,28. Further, recent work, a U.S.-based prospective registry (TBCRC013) and 
two randomized clinical trials from Turkey and India29–31, have reported conflicting results regarding the impact 
of PT locoregional treatment on OS. Therefore, international guidelines recommend PT surgery only in selected 
patients while awaiting for the final results of ongoing clinical trials (ECOG 2108/NCT0124800, SUBMIT/
NCT01392586, JCOG 1017/UMIN000005586 y ABCSG 28/POSYTIVE/NCT01015625)32.
The biological mechanisms underlying the aforementioned results involve the crosstalk among the PT and 
metastatic foci, PT immunosuppressive effects, and/or the prevention of metastatic re-seeding from the primary 
source. Yet, the surgical procedure itself may have negative impacts such as a transient inflammation, turning on 
the “angiogenic switch” in the wound healing process, and a temporary immunosuppressive state which, subse-
quently, might imbalance microenvironment-tumor interactions eventually triggering the metastatic cascade33–37.
The main aim of this work was to study the prognostic value of PT surgical excision, in the presence of other 
well-known prognostic factors, in MBC patients with OS as the outcome of interest. The objective of the analysis 
was to clarify the role of a locoregional approach to the PT in de novo MBC patients in a real-world retrospective 
series. Our ultimate purpose is to evaluate this treatment as a valid option to be included in the national clinical 
protocol for this patient population. All patients were diagnosed and treated in various Spanish health care insti-
tutions included under the umbrella of GEICAM Spanish Breast Cancer Group.
patients and Methods
El Álamo study is a cooperative epidemiologic initiative conducted by GEICAM in order to characterize breast 
cancer (BC) cases diagnosed in Spain. El Álamo is a retrospective registry of patients diagnosed with BC between 
1990 and 2001 across 56 Spanish hospitals. The patterns of BC presentation (tumor and host characteristics), the 
different treatments received, and the clinical evolution of the disease were described and structured in 3 cohorts 
collected in consecutive 4-year intervals as follows: El Álamo I (1990–1993, 4551 patients, closed by 2000), El 
Álamo II (1994–1997, 10849 patients, closed by 2003) and El Álamo III (1998–2001, 10675 patients, closed by 
2007). This database is estimated to comprise approximately 15% of the newly diagnosed BC cases in Spain 
within this period and to reflect clinical practice in the country at each time point. Participating investigators, 
which included all the medical oncology department staff members of the participating hospitals, were required 
to include all BC patients seen in those institutions over the entire annual study period.
Only women with invasive de novo MBC were included in the current analysis. Patients with stage I–III at 
initial diagnosis and later recurrence, with secondary tumors, with fewer than 2 months’ follow-up at the same 
institution, and with missing data regarding their PT surgery were excluded. The criteria to perform PT surgery 
were defined by institutional guidelines as per investigator discretion.
A total of 39 variables including demographic (age and menopausal status), primary tumor staging (TNM 
classification), pathology (hormonal receptor status, grade and histological type), and local plus systemic treat-
ment data were selected for this analysis.
Data were collected following the requirements of the Spanish legislation for privacy data protection at the 
time: the Spanish Organic Law of December 13th, 1990 of Personal Data Protection. Observational retrospective 
studies based on patient charts required neither patient informed consent nor ethical committee approval. We 
submitted our study to a present-day ethical committee, Hospital Universitario Parc Tauli at Barcelona, which 
reviewed and confirmed the procedures followed guaranteed patient’s data confidentiality and were in compliance 
with the rules established at that time.
Statistical Analysis
Categorical variables were expressed as the absolute and relative frequencies. Continuous data were expressed 
as central tendency and dispersion measures (mean, median, trends, range). Baseline differences in categorical 
variables were assessed by the Chi Square test (Χ2) or the Fisher exact test when appropriate. OS was defined as 
the time from the year of diagnosis to death from any cause or to last follow-up visit. OS curves were estimated 
using the Kaplan-Meier method and survival functions among the different subgroups were compared with the 
log-rank exact test. The impact of our main variable of interest (PT surgery) and clinically relevant variables 
(metastatic location, patient’s menopausal status, and tumor’s characteristics including histological type, histo-
logical grade, HER2 status, hormone receptor status, Ki67, expression level of p53, BC subtype, and tumor size) 
on OS was estimated using Cox proportional hazards regression models. The proportional Hazards assumption 
was checked using the test based on the correlation coefficient between survival time and the scaled Schoenfeld 
residuals. All tests were performed using an alpha of 0.05.
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Analyses were performed using the program R and the Statistical Analysis System (SAS) package (Enterprise 
Guide 5.1 software, SAS Institute Inc., Cary, NC, USA).
Results
Descriptive analyses. We selected 1415 (5.5%) patients with de novo MBC from the database El Álamo. Of 
these, 1331 patients (327 patients from El Álamo I, 619 patients from El Álamo II, and 385 patients from El Álamo 
III) met the eligibility criteria to be included in this analysis (Fig. 1). Table 1 shows patient and tumor character-
istics, and treatment received. Median age was 63.1 years (range: 21.6–96.0) and 49.2% of them had single-organ 
metastasis. The metastatic disease was anatomically distributed as follows: skin/soft tissue (16.3%), bone (33.8%), 
viscera (48.3%) and unknown/unavailable (8.6%).
Initial local treatment was the choice for 380 (28.5%) patients (358 surgery and 22 radiotherapy), 722 (54.2%) 
patients received initial systemic therapy (480 chemotherapy [CT], 214 endocrine treatment [ET] and 28 both 
CT and ET), 29 (2.2%) received best supportive care and for the rest of patients the treatment sequence could not 
be established (Fig. 2).
PT surgery, at any time of the patient evolution, was performed in 44.5% (N = 592) patients (512 radical pro-
cedures [86.5%], 46 palliative procedures [7.8%], and 34 unknown [5.7%]). Out of the 592, 427 (72.1%) patients 
underwent axillary lymph node dissection. Compared to women in the non-surgery group (non-S), women in 
the surgery group (S) were younger (19.4% of the S group versus 11.8% of the non-S group were ≤44 years-old, 
respectively), a higher percentage presented with oligometastatic disease (defined as metastases limited to a single 
organ) than not (57.4% versus 42.6%, respectively), were more likely to have smaller (i.e. ≤T2) tumors (49.2% 
versus 22.7%, respectively), and were less likely to present visceral disease (40.3% versus 54.4%) but more likely to 
present bone metastases (39% versus 29.8%, respectively).
Survival analysis. With a median follow-up of 23.3 months, median OS was 28.6 months (95% Confidence 
Interval [CI], 26.0–31.2). At 1 year, 75.3% of patients (95%CI, 72.9–77.6) were alive, 42.6% remained alive at 3 
years (95%CI, 39.8–45.4), and only 25.4% (95%CI, 22.8–28) were alive at 5 years (Fig. 3a).
Median OS in the S group was 39.6 months (95%CI, 35.4–43.9) compared to 22.4 months (95%CI, 20.7–24.2) 
in the non-S group (Hazards Ratio [HR] 0.59, 95%CI, 0.52–0.68; p < 0.0001). At 1 year, 83.6% of patients (95%CI, 
80.5–86.6) were alive in the S group compared to 68.6% (95%CI, 65.2–72.0) in the non-S group. This S group 
survival advantage was maintained in the following years with 53.7% of patients (95%CI, 49.4–57.9) being alive 
in the S group versus 33.5% (95% CI, 29.9–37.2) in the non-S group at 3 years. Finally, at 5 years, survivors 
decreased to 33.5% of patients (95%CI, 29.3–37.8) in the S group versus 18.7% (95% CI, 15.5–21.9) in the non-S 
group (Fig. 3b).
Subgroup OS analysis also showed a consistent benefit among the S group across all selected categories of 
tumor characteristics (Fig. 4).
Univariate analysis for the entire de novo MBC group in the El Álamo registry. PT surgery, metastatic location, 
histological type, histological grade, hormone receptor status, BC subtype, and tumor size were statistically signif-
icant prognostic factors for OS in the univariate Cox analysis. On the other hand, menopausal status (p = 0.144), 
HER2 status (p = 0.061), Ki67 (p = 0.972), and p53 (p = 0.504) failed to have a significant impact on OS (Table 2).
Multivariate analysis for the entire de novo MBC group in the El Álamo registry. Adjusting for all relevant 
clinical variables in a multivariate model (except BC subtypes and HER2 due to their small sample sizes), the 
fully-adjusted HR for PT surgery was 0.685 (95%CI, 0.591–0.793; p < 0.001). All the following variables were 
Figure 1. Patient selection flowchart.
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Category
Surgery
N = 592 (%)
Non-Surgery
N = 739 (%) p value*
Age (years) <0.0001
≤44 115 (19.4) 87 (11.8)
45–64 240 (40.5) 283 (38.3)
≥65 236 (39.9) 367 (49.6)
NA 1 (0.2) 2 (0.3)
Menopausal status 0.0001
Postmenopausal 419 (70.8) 589 (79.7)
Premenopausal 168 (28.4) 144 (19.5)
NA 5 (0.8) 6 (0.8)
Tumor size (TNM) <0.0001**
T0 5 (0.8) 5 (0.7)
T1 63 (10.6) 39 (5.3)
T2 223 (37.8) 124 (16.8)
T3 60 (10.1) 84 (11.4)
T4 212 (35.8) 372 (50.2)
NA 29 (4.9) 115 (15.6)
Histological type <0.0001***
Ductal 426 (72) 322 (43.6)
Lobular 42 (7.1) 48 (6.5)
Mucinous (colloid) 5 (0.8) 2 (0.3)
Mixed 8 (1.4) 2 (0.3)
Tubular 2 (0.3) 2 (0.3)
Medullary 1 (0.2) 1 (0.1)
Papillary — 1 (0.1)
Adenocarcinoma (NS) 16 (2.7) 72 (9.7)
Others (non-adenocarcinoma or NA) 92 (15.5) 289 (39.1)
Histological grade 0.2734
GI 31 (5.2) 20 (2.7)
GII 163 (27.5) 63 (8.5)
GIII 138 (23.3) 57 (7.7)
NA 260 (44) 599 (81.1)
Hormone Receptor status 0.4216
Positive 286 (48.3) 180 (24.4)
Negative 102 (17.2) 55 (7.4)
NA 204 (34.5) 504 (68.2)
HER2 status 0.1243
Positive 30 (5.1) 22 (3.0)
Negative 100 (16.9) 44 (6.0)
NA 462 (78.0) 673 (91.0)
Ki67 (cut-off 13%) 0.3309
High (>13%) 24 (4.1) 13 (1.8)
Low (≤13%) 14 (2.4) 4 (0.5)
NA 554 (93.5) 722 (97.7)
p53 0.4370
Positive 25 (4.2) 7 (0.9)
Negative 28 (4.7) 12 (1.6)
NA 539 (91.1) 720 (97.5)
BC Subtypes 0.0758
HR positive/HER2 negative 76 (12.8) 27 (3.7)
HER2positive 30 (5.1) 22 (3)
Triple Negative 18 (3.0) 5 (0.7)
NA 468 (79.1) 685 (92.6)
Number of organs with metastasis <0.0001
1 340 (57.3) 315 (42.6)
2 100 (16.9) 170 (23.0)
≥3 76 (12.9) 196 (26.5)
Continued
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found to be statistically significant in the final multivariate Cox regression analysis: metastatic location, histo-
logical type, histological grade, hormone receptor status and tumor size (Table 3). Given that HRs for metastatic 
location and histological type did not meet the proportional hazard assumption, we carried out a sensitivity anal-
ysis stratifying the cohort according to these two factors. The HR for PT surgery was virtually unchanged (0.685 
in the final model versus 0.684 in the stratified model).
Restricted multivariate analysis (low risk). Due to the observational nature of the El Álamo study and in order 
to avoid a possible confusion due to indication bias, we performed an exploratory sensitivity analysis for patients 
with extreme favorable prognostic features. The definition of this “low risk” population comprised patients with 
small tumor size (≤T2) and oligometastatic disease. We repeated the multivariate Cox regression analysis in this 
particular subgroup of “low risk” de novo MBC patients (N = 252).
The median OS for the low-risk subgroup was 40.4 months (95%CI, 33.2–47.7) with 53.2% (95%CI, 46.7–
59.7%) of patients being alive at 3 years. The fully adjusted HR for PT surgery was 0.742 (95%CI, 0.518–1.063; 
p = 0.103), i.e., it failed to be a prognostic factor for this low-risk subgroup. However, metastatic location, histo-
logical type, and histological grade remained statistically significant predictors of survival. In addition, year of 
diagnosis (i.e., El Álamo cohort) was also a significant prognostic factor in this patient subgroup.
Subgroup analysis based on the approach for the primary tumor. Table 4 shows a subgroup analysis including 
metastatic location, histological type, histological grade, hormone receptor status, El Álamo cohort, BC subtype, 
tumor size, and number of metastases. Median OS was greater in patients with PT surgical excision regardless of 
Category
Surgery
N = 592 (%)
Non-Surgery
N = 739 (%) p value*
NA 76 (12.9) 58 (7.9)
Metastatic location N = 528 N = 689 <0.0001
Skin/Soft tissue 96 (18.2) 102 (14.8)
Bone 206 (39.0) 205 (29.8)
Visceral 213 (40.3) 375 (54.4)
NA 13 (2.5) 7 (1.0)
Table 1. Patient characteristics by surgical management of primary tumor for the entire group de novo MBC 
patients from El Álamo registry. Abbreviations: MBC, metastatic breast cancer; NA, not assessed; T, tumor size; 
NS, non-specific; G, grade; BC, breast cancer; HR, hormone receptor; HER2, human epidermal growth factor 
receptor 2. *p-value calculated not considering NA or Other data; **Patients with T0 and T1 tumors were 
combined; ***ductal versus others.
Figure 2. Local and systemic treatments administered to de novo MBC patients and corresponding survival 
outcomes from El Álamo registry.
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Figure 4. Subgroup analysis of overall survival from El Álamo registry.
Figure 3. Overall survival for El Álamo registry patients. (a) Overall Survival for all de novo metastatic breast 
cancer patients; (b) Overall survival by surgery and no-surgery groups of the primary tumor.
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metastatic location (visceral, bone, skin/soft tissue), histological type, hormone receptor status, El Álamo cohort, 
tumor size, and whether they had single or multiple metastases. However, this benefit failed to reach statistical 
significance when evaluating it by BC subtypes (due to small sample sizes) or for patients with histological grade 
III tumors.
Variable N Events Censored Hazard Ratio (95%CI) p-value
Surgery <0,0001
Yes 587 384 203 0.592 (0.520–0.675)
No 729 560 169 Ref.
Metastatic location <0.0001
Visceral 578 455 123 Ref.
Bone (if non visceral) 408 276 132 0.606 (0.521–0.704) <0.0001
Soft tissue (if non visceral non bone) 196 129 67 0.568 (0.466–0.691) <0.0001
Menopausal status 0.144
Premenopausal 308 230 78 Ref.
Postmenopausal 997 707 290 1.117 (0.963–1.297)
Histological type 0.006
Ductal 738 516 222 Ref.
Other 216 163 53 1.282 (1.074–1.529)
Histological grade 0.001
G I-II 273 184 89 0.676 (0.542–0.844)
G III 194 139 55 Ref.
HER2 status 0.061
Positive 51 35 16 Ref.
Negative 140 85 55 0.685 (0.461–1.017)
Hormone receptor status 0.001
Positive 459 309 150 0.686 (0.550–0.854)
Negative 155 108 47 Ref.
Ki67 0.972
0–13 18 13 5 0.988 (0.485–2.009)
>13 36 19 17 Ref.
P53 0.504
Positive 31 17 14 Ref.
Negative 40 27 13 0.811 (0.439–1.499)
El Álamo cohort 0.003
El Álamo I 327 248 79 Ref.
El Álamo II 611 438 173 0.882 (0.755–1.031)
El Álamo III 378 258 120 0.742 (0.623–0.884)
BC Subtype 0.039
TN 23 12 11 Ref.
HER2positive 51 32 16 1.523 (0.790–2.937)
HR positive/HER2 negative 99 57 42 0.881 (0.473–1.642)
Tumor size (TNM) <0.0001
T0 10 5 5 0.322 (0.133–
T1 101 58 43 0.779)
T2 344 236 108 0.549 (0.417-
T3 143 103 40 0.723)
T4 574 437 137 0.740 (0.631–0.867)
0.886 (0.715–1.099)
Ref.
Number of metastases <0.0001
Single-organ metastasis 650 443 207 0.703 (0.615–0.804)
Multiple metastases 532 417 115 Ref.
Table 2. Univariate analysis of overall survival for the entire group of de novo MBC patients from El Álamo 
registry. Abbreviations: MBC, metastatic breast cancer; CI: Confidence interval; G, grade; BC, breast cancer; 
TN, triple negative; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; T, tumor size.
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Discussion
The OS benefit observed in de novo MBC patients from El Álamo registry undergoing PT surgery supports pre-
vious findings reported by contemporary population-based registries14,38–43. Two meta-analyses found that PT 
surgery in these patients was independently associated with improved survival, HR of 0.63–0.6922,23, ranging 
from 0.5 to 0.8 in the individual series. However, since other studies failed to detect any benefit from PT sur-
gery44–46, findings in this field remain inconclusive. El Álamo data yielded a median OS of 39.6 versus 22.4 months 
(HR = 0.59, p < 0.0001), for the S and non-S group, respectively. These figures are comparable to the most favora-
ble data reported by previous studies.
De novo MBC patients represented 5.5% of the entire BC patient population included in the El Álamo regis-
try. PT surgery was performed in 44.5% of them. These results align with previously reported population-based 
evidence from other European registries39,41. In El Álamo registry 54.2% of patients received primary systemic 
therapy and underwent surgery later on.
Although retrospective studies offer valuable information in a very efficient, cost-effective manner, prospective 
studies are needed to confirm any findings and advance knowledge. For instance, prospective analyses from a US 
population multicentre registry29 recently showed that patients selected for surgery were more likely to have oli-
gometastatic disease and to receive first-line chemotherapy. Among responders, surgery was not associated with 
improved survival for any BC subtype. Several clinical trials were designed to prospectively address this finding, 
but results from the two randomized trials already reported failed to provide a satisfactory answer. A Turkish study 
(MF07–01)30 requiring randomization to loco-regional therapy (LRT) before systemic therapy, reported an OS 
benefit from initial surgery (median OS of 46 versus 37 months in the S and non-S groups, respectively [HR 0.66, 
p = 0.005]), suggesting a potential benefit mainly in patients with bone-only metastases (supporting our results), 
in patients with ER positive/HER2 negative tumors, as well as in younger patients. In contrast, the Tata Memorial 
study31 requiring induction systemic therapy prior to randomization, reported no LRT impact on OS in patients 
Variable N Hazard Ratio 95%CI p-value
Surgery <0,001
Yes 587 0.685 (0.591–0.793)
No 729 Ref.
Metastatic location <0,001
Visceral 578 Ref.
Bone (if non visceral) 408 0.674 (0.578–0.787)
Soft tissue (if non bone non visceral) 196 0.554 (0.452–0.680)
NA 134 0.697 (0.547–0.886)
Histological type 0,003
Ductal 738 Ref.
Other 216 1.249 (1.041–1.498)
NA 362 0.863 (0.725–1.028)
Histological Grade 0.009
G I-II 273 0.721 (0.576–0.904)
G III 194 Ref.
NA 849 0.755 (0.613–0.929)
Hormone Receptor status <0.001
Positive 459 0.676 (0.539–0.848)
Negative 155 Ref.
NA 702 0.983 (0.780–1.241)
El Álamo cohort 0,213
El Álamo I 327 Ref.
El Álamo II 611 0.940 (0.798–1.108)
El Álamo III 378 0.839 (0.687–1.025)
Tumor Size (TNM) 0.048
T0 10 0.358 (0.147–0.873)
T1 101 0.708 (0.534–0.939)
T2 344 0.887 (0.753–1.046)
T3 143 0.930 (0.748–1.156)
T4 574 Ref.
NA 144 0.967 (0.779–1.200)
Table 3. Multivariate analysis for overall survival for the entire de novo MBC patients from El Álamo registry*. 
Abbreviations: MBC, metastatic breast cancer; CI: confidence interval, NA not-assessed; G, grade; T, tumor 
size. *Even though the variable “Number of metastases” was statistically significant in the univariate analysis, it 
was not included in the multivariate model because of a multicollinearity problem with the variable “metastatic 
location”.
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who responded to front-line chemotherapy (median OS of 19.2 versus 20.5 months in the LRT versus non-LRT 
groups [HR 1.04, p = 0.79]). Nonetheless, local progression-free survival (PFS) was significantly better in patients 
who had LRT (HR 0.16, p < 0.001) in contrast with the significant detriment in distant PFS in patients receiving 
LRT (HR 1.42, p = 0.012). No differences in survival were detected in the planned subset analysis. In addition, pre-
liminary results from the ABCSG 28 study47 comparing initial PT surgery versus initial systemic treatment in only 
90 patients (the study was terminated early due to low accrual) failed to find OS benefit for immediate PT surgery 
(HR 0.69, p = 0.267). Two other studies (JCOG1017 and ECOG2108) testing the value of surgery after primary 
systemic treatment are currently ongoing. Although it is agreed upon that level 1 evidence, e.g., prospective data 
from these randomized-controlled trials like these, is highly needed to close this long-lasting debate, it remains 
difficult to obtain in a timely manner. Moreover, the interpretation of their results should be done carefully from a 
methodological perspective and contextualized with the available body of real-world evidence48.
Our results should be interpreted in the context of the study’s and registry’s limitations. For instance, despite 
the current evidence of the importance of achieving PT surgery with negative margins for improved out-
comes38,39,49 this information was not available in El Álamo database. Similarly, the database did not address the 
highly relevant aspect of the impact on survival of PT local radiation therapy, usually studied as part of a multi-
modal locoregional approach. Thus, whether there is an actual benefit of radiotherapy by itself in this setting, the 
optimal dose, and fractionation remain unknown26 and, thus, cannot be recommended as a standard procedure.
Additionally, because of the observational nature of our series, we performed a multivariate sensitivity analysis 
in the “low risk” de novo MBC patient subgroup. By reducing the heterogeneity of both known and unknown 
prognostic factors potential biases are reduced. Results showed that the prognostic value of PT excision surgery 
was preserved overall, strongly suggesting that the response of this “low-risk” subgroup of patients to PT surgery 
is not different from that of the de novo MBC patient population under study.
Subgroup
Number of events/patients (%) Median OS (months) (95%CI)
Non-Surgery Surgery Non-Surgery Surgery
Alla 560/729 (77) 384/587 (65) 22.4 (20.7–24.2) 39.6 (35.4–43.9)
Metastatic location
Viscerala 300/367 (82) 155/211 (73) 18.1 (14.7–21.4) 27.9 (20.8–35.0)
Boneb 140/204 (69) 136/204 (67) 30.6 (25.2–35.9) 42.5 (35.5–49.6)
Skin and Soft tissuea 76/101 (75) 53/95 (56) 21.9 (18.1–25.7) 52.1 (37.5–66.8)
Histological type
Ductala 246/316 (78) 270/422 (64) 23.4 (21.2–25.6) 38.7 (33.9–43.6)
Othera 113/138 (82) 50/78 (64) 16.0 (10.1–22.0) 37.9 (19.8–56.0)
Histological grade
G I-IIa 66/82 (80) 118/191 (62) 25.0 (18.2–31.8) 49.7 (40.8–58.6)
G IIIc 43/56 (77) 96/138 (70) 21.2 (12.5–29.9) 29.4 (20.6–38.3)
Hormone receptor status
Positivea 130/176 (74) 179/283 (63) 31.8 (26.3–37.4) 46.5 (40.6–52.3)
Negatived 44/54 (81) 64/101 (63) 20.8 (10.6–30.9) 23.6 (10.2–36.9)
El Álamo cohort
El Álamo Ia 159/203 (78) 89/124 (72) 21.2 (17.6–24.8) 35.6 (28.1–43.2)
El Álamo IIa 275/357 (77) 163/254 (64) 21.9 (19.6–24.2) 38.0 (32.0–44.0)
El Álamo IIIe 126/169 (75) 132/209 (63) 25.3 (17.8–32.7) 43.6 (35.5–51.7)
BC subtype
Triple negative 5/5 (100) 7/18 (39) 40 (0–94.0) —
HER2 positive (regardless HR status) 12/21 (57) 23/30 (77) 38.3 (16.4–60.2) 41.8 (29.3–54.3)
HR positive and HER2 negative 17/25 (68) 40/74 (54) 39.3 (26.3–52.4) 52.4 (39.9–64.9)
Tumor size (TNM)
T0 2/5 (40) 3/5 (60) — 59.2 (10.7–107.7)
T1f 27/38 (71) 31/63 (49) 23.9 (16.8–30.9) 64.2 (42.4–86.1)
T2a 93/123 (76) 143/221 (65) 24.0 (19.2–28.7) 40.0 (32.4–47.6)
T3g 62/83 (75) 41/60 (68) 24.2 (16.2–32.3) 41.0 (20.1–61.9)
T4a 291/365 (80) 146/209 (70) 21.6 (19.2–24.0) 35.1 (30.4–39.8)
Number of metastases
Single-organ metastasisa 228/313 (73) 215/337(64) 24.5 (22.1–26.9) 40.4 (34.5–46.3)
Multiple metastasese 287/358 (80) 130/174 (75) 20.8 (17.3–24.2) 32.1 (28.2–36.0)
Table 4. Subgroup analysis of overall survival in the surgery and non-surgery groups from El Álamo registry. 
Abbreviations: OS, overall survival; G, grade; BC, breast cancer; HER2, human epidermal growth factor 
receptor 2; HR, Hormone receptor; T, tumor size. ap < 0.0001; bp = 0.037; cp = 0.083; dp = 0.009; ep = 0.001; 
fp = 0.002; gp = 0.026.
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Further, certain limitations of our data could confound the association between PT surgery and survival, 
thus affecting how our results inform decision-making algorithms in clinical practice. Specifically, two sources of 
potential bias should be recognized as selection biases. First, the stage migration phenomenon defining stage IV 
MBC (TNM-staging classifications changed between 1990 and 2001 in the definition of N3 supraclavicular nodes 
versus M1); and second, the non-standardized indication of the local procedure which was conducted on a case 
by case basis, with no pre-defined criteria, based on the physician’s discretion.
Also, the lack of on-site monitoring of data compilation and data quality at the different institutions intro-
duces an additional source of variability. Thus, we consider the amount of missing data for the following variables 
another study limitation: hormone receptor and HER2 status for the molecular sub-classification of patients, 
surgical procedures, pathological margin status, and chronological order of administration of loco-regional and 
systemic therapies.
This study also has important strengths. First, to our knowledge this is the largest series performed in Spain 
(N = 1331) assessing the role of PT surgery in de novo MBC patients’ survival. Second, the wide geographical 
distribution of cases throughout Spain in the late nineties captures the clinical practices in place at that time to 
manage the controversial aspect of PT surgery as part of the management of a very small but remarkable group 
of patients. Clinical practices have changed over the last 10–15 years as new treatments have been added to the 
therapeutic armamentarium. This progress may limit the translational value of the El Álamo results to current 
clinical practice, but there are still valuable lessons to be learned from them. To address these limitations El 
Álamo IV (NCT03210974) registry is currently ongoing covering the 2002–2005 period. Moreover, GEICAM is 
also running, in a parallel fashion, a multicenter prospective registry in the metastatic disease setting (RegistEM, 
NCT02819882) which will allow the study of how primary tumors are locally managed in a real clinical setting.
Finally, the prognostic value of PT surgical resection may vary by intrinsic subtype, global burden of dis-
ease, and/or characteristics of the de novo MBC patients. The definition of the best timing to perform the local 
approach remains open in the era of molecularly targeted therapy. This is also the case for the need for radiation 
therapy, the type of surgery required (with or without axillary resection), or even the possibility of foregoing sur-
gery altogether in favor of full radiation treatment.
conclusions
In the El Álamo registry local PT surgery was associated with better OS independently of metastatic location, 
histological type, histological grade, hormone receptor status, and tumor size. These analyses suggest that LRT 
of PT should be considered as part of the therapeutic strategy for selected patients with advanced disease. Thus, 
this strategy must be further investigated in randomized controlled trials for de novo MBC patients to control for 
potential bias intrinsically associated with retrospective studies. Pre-clinical models and translational correlative 
studies are needed to understand the biology behind the effect of LRT to the PT in this setting.
Ethical approval and inform consent. Data were collected following the requirements of the Spanish 
legislation for privacy data protection in the considered period. The specific legislation is the Spanish Organic 
Law of December the 13th, 1990 of Personal Data Protection.
The specific regulation for observational retrospective studies was developed in Spain in 2009 with the 
December 16th ORDER SAS/3470/2009, which publishes guidelines on post-authorization observational studies 
for drugs for human use. The ALAMO study was performed before this legislation was in place so the ethical 
committees in Spain did not review any observational retrospective study before this legislation was developed.
According to the current regulations for observational retrospective studies in force the informed consent 
of the subjects is not required since: (1) in the process of data collection retrospectively, a secure dissociation 
procedure is adopted, ensuring that the information handled in the study does not contain personal data and (2) 
personal interviews are not required nor are biological samples collected from patients. Each patient receives a 
number identification for their participation in the study.
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Data are available from the corresponding author upon reasonable request.
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